Press Releases

15 Mar 2021

Updated 21 Jan 2022

EvidentIQ group to launch new eCOA and eFeasibility offerings combining scientific services with a comprehensive software suite usable on any device.


EvidentIQ group to launch new eCOA and eFeasibility offerings combining scientific services with a comprehensive software suite usable on any device.

HAMBURG, Germany,  March 15th, 2021 – Data science group EvidentIQ with operations in Germany, France and the US, announced today the launch of their next generation eCOA and eFeasibility solutions for CROs and study sponsors. In a rapidly growing market, the EvidentIQ offering stands out as it combines a comprehensive tech stack with proven scientific services to support pharmaceutical companies, CROs and sponsor teams throughout the feasibility and clinical outcome data collection phase of their clinical trials.

With its comprehensive eCOA solution, the new data science group, which has only recently been built by merging long-established providers XClinical, Carenity and Fortress Medical, has set out to fuse data science services and a scalable software platform. EvidentIQ customers benefit from an end-to-end eCOA package allowing to collect any patient / clinician / observer reported outcome data in a streamlined, compliant and efficient way. The solution can be used stand-alone or fully integrated into existing eClinical technologies, such as EDC systems. The EvidentIQ eCOA offering supports a bring-your-own-device (BYOD) policy and works on any iOS/Android phone.

Combining a software platform with scientific services

EvidentIQ’s combined offering of a platform with a scientific service offering attached to it empowers LifeScience professionals to conduct virtual and hybrid clinical trials. Unique eFeasibility solutions help optimize clinical trials and accelerate patient recruitment with a patient-centric approach.

EvidentIQ relies on Data Science and robust technologies to custom the design of clinical trials optimizing Product Profiles, Endpoints, Protocols, ICFs, and eCRFs. The package facilitates a complete digitalized patient enrollment journey for clinical trials from Multi-channel Pre-screening over eConsent Management to the Clinical Data Capture in the EDC.  

Steady Market Growth for eCOA

Andreas Weber, CEO of EvidentIQ, points out the substantial market growth for Electronic Clinical Outcome Assessment:

“Most market analyses expect a CAGR of more than 15% for the eCOA market until 2027, and a global market volume of approximately 2.5 billion USD by then.”

When asked for the main drivers causing this growth Weber sees multiple developments besides the global Covid-19 pandemic.

“Keep in mind there is a high demand for clinical trials in emerging markets and consistently high R&D spendings in the pharmaceutical industry. Besides FDA and EMA are taking a tougher stance on COA data collection meeting regulatory quality guidelines.”

“Our new eCOA offering demonstrates perfectly how we create value for our customers and in doing so build a unique market position for our group. We empower life science companies of all sizes to transition from outdated, error-prone paper-based processes to digital data capture and data processing.”

Contact us for more information on eCOA by EvidentIQ

Get a Demo

Let us show you how we can help you.

Get a Quote

Discover a solution tailored to your needs and budget.

Get a Meeting

Let’s start a new project together!

Let’s Start
a conversation

Ready to discover how our platform and its suite of applications can meet your needs?


    We use cookies to personalize content and ads, provide social media features, and analyze traffic to our website. Our partners may combine this information with other data they have provided to you or collected from your use of the services. Because we value your privacy, we hereby request your permission to use the following technologies. You may change / revoke your consent later at any time by clicking on the settings in the lower left corner of the page.

    Please note that according to a recent ruling by the European Court of Justice (ECJ), there is no adequate level of data protection in the USA and therefore a risk to the protection of your data. For example, under certain conditions, your data may be processed by US authorities for control and monitoring purposes. In addition, we currently refer to Art. 49 GDPR with regard to the legal basis for the transfer of data. After implementation of the new EU standard data protection clauses, these will constitute the legal basis for data transfer to third countries.